Syros Pharmaceuticals Acquires Tyme Technologies in $130M PIPE and Closes Merger

Symeres Acquires Oncolines

January 10, 2023

Healthcare Services

Symeres, the Netherlands-headquartered transatlantic CRO & CDMO backed by Keensight Capital, has acquired Oncolines, an Oss-based oncology-focused CRO that provides early biology services and cell-line profiling assays. The add-on expands Symeres' oncology and precision-medicine biology capabilities and brings Oncolines' ~20 employees into the Symeres platform (part of NTRC Holding), increasing the group's integrated drug-discovery offering and proforma revenues to over €100m.

N-Power Medicine Acquires Syapse

December 30, 2024

Healthcare Services

N-Power Medicine completed a stock-for-stock acquisition of Syapse on December 30, 2024, integrating Syapse’s precision-medicine technology, data assets and network of community oncologists into N-Power’s Kaleido Registry and AI-enabled point-of-care platform. Innovatus Capital Partners joined N-Power’s existing investors (including the Merck Global Health Innovation Fund) to provide ongoing funding; Canaccord Genuity served as Syapse’s exclusive financial advisor.

Novartis to Acquire MorphoSys in $2.9 Billion Deal

February 7, 2024

Pharmaceuticals

Novartis agreed to a voluntary public takeover offer to acquire MorphoSys AG for €68 per share, valuing the deal at about €2.7 billion (reported as $2.9 billion). The acquisition is intended to expand and complement Novartis’ oncology pipeline, including pelabresib (CPI-0610) and tulmimetostat (CPI-0209).

Ipsen Acquires Epizyme to Expand Oncology Portfolio

August 12, 2022

Pharmaceuticals

Ipsen completed its acquisition of Epizyme under a definitive merger agreement, acquiring all outstanding shares for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. The deal expands Ipsen’s oncology portfolio with Epizyme’s lead medicine Tazverik (tazemetostat) and development candidate EZM0414, among other preclinical programs.

Bristol Myers Squibb Acquires RayzeBio in $4.1B Deal

December 26, 2023

Biotechnology

Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in an all-cash transaction, valuing the equity at approximately $4.1 billion. The deal is expected to close in the first half of 2024, subject to customary conditions, bringing RayzeBio’s actinium-based radiopharmaceutical platform and clinical pipeline into BMS’s oncology franchise.

BioPharmX Corp to Merge with Timber Pharmaceuticals

January 28, 2020

Pharmaceuticals

BioPharmX Corporation (NYSE American: BPMX) entered into a definitive merger agreement with Timber Pharmaceuticals LLC whereby a BioPharmX subsidiary will merge into Timber, leaving Timber as a wholly‑owned subsidiary of BioPharmX. The transaction will bring at least $20 million of financing to the combined company, after which BioPharmX will change its name to Timber Pharmaceuticals and Timber’s management will become the combined company's leadership.